Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479934 | 1.00 | CRHBP (0.44) | CRHBPCRHR2MEN1MAPTKMT2A | |
| SCHEMBL15275536 | 0.80 | GABRA1 (0.41) | MAPTKMT2ALMNA | |
| SCHEMBL12786256 | 0.77 | MEN1 (0.44) | CRHBPCRHR2MEN1MAPTKMT2A | |
| SCHEMBL6395417 | 0.76 | — | — | |
| SCHEMBL2850698 | 0.75 | SLC6A2 (0.30) | — | |
| SCHEMBL1315082 | 0.72 | MAPK1 (0.32) | ACHE | |
| SCHEMBL30480018 | 0.72 | MAPK1 (0.32) | ACHE | |
| SCHEMBL4008294 | 0.70 | CA1 (0.37) | LMNA | |
| SCHEMBL2852138 | 0.70 | TAAR1 (0.39) | HTR2ASLC6A4 | |
| SCHEMBL6733419 | 0.68 | MAPT (0.38) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233961-B9 | METHOD FOR PRODUCING 5-(1-PIPERAZINYL)-BENZOFURAN-2-CARBOXAMIDE BY TRANSITION METAL-CATALYZED AMINATION | MERCK PATENT GMBH (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-1233961-B1 | METHOD FOR PRODUCING 5-(1-PIPERAZINYL)-BENZOFURAN-2-CARBOXAMIDE BY TRANSITION METAL-CATALYZED AMINATION | MERCK PATENT GMBH (DE) | 2005-07-06 | — | — | EP | disclosed |
| US-6762300-B2 | ONE POT; SUCH AS CYCLIZATION OF 5-BROMOSALICYLALDEHYDE WITH ETHYL BROMOACETATE AND REACTING WITH FORMAMIDE THEN WITH PIPERAZINE DERIVATIVE | MERCK PATENT GMBH (DE) | 2004-07-13 | — | — | US | disclosed |
| US-20030125558-A1 | Method for producing 5-(1-piperazinyl) -benzofuran-2-carboxamide by transition metal-catalyzed amination | MERCK PATENT GMBH (DE) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125558-A1 | Method for producing 5-(1-piperazinyl) -benzofuran-2-carboxamide by transition metal-catalyzed amination | PARP15, TPMT, TPH2 | CRHBP 2781/4885CRHR2 1489/4885MEN1 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.